# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 81-90 of 574 results.
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
Status: Recruiting
Last Changed: Sep 15, 2017
First Received: Sep 13, 2017
Disease(s): B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma
Intervention(s): PZ01 CAR-T cells
Locations: Department of Hematology, Navy General Hospital of PLA, Beijing, Beijing, China
CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Oct 29, 2019
First Received: Sep 19, 2017
Disease(s): Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, DLBCL
Intervention(s): AUTO3
Locations: Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center/Sarah Cannon Research Institute, Denver, Colorado, United States
TriStar Centennial Medical Center /Sarah Cannon Research Institute, Nashville, Tennessee, United States
St David's South Austin Medical Center /Sarah Cannon Research Institute, Austin, Texas, United States
University College London Hospitals NHS Foundation Trust, London, United Kingdom
Manchester University NHS Foundation Trust, Manchester, United Kingdom
... and 2 other locations.
In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Status: Recruiting
Last Changed: Jan 24, 2019
First Received: Nov 06, 2013
Disease(s): Low-Grade B-cell Lymphoma
Intervention(s): rhuFlt3L/CDX-301, Poly-ICLC
Locations: Icahn School of Medicine at Mount Sinai, New York, New York, United States
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
Status: Recruiting
Last Changed: Mar 21, 2019
First Received: Mar 19, 2019
Disease(s): B-Cell Lymphoma Stage I, Refractory, Relapsed
Intervention(s): CD19/CD20 bispecific CAR-T cells
Locations: Cancer Hospital Affiliate to Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs
Status: Recruiting
Last Changed: Nov 30, 2018
First Received: Nov 17, 2017
Disease(s): Primary Mediastinal Large B-cell Lymphoma
Intervention(s): Decitabine, GVD chemotherapy, SHR-1210
Locations: Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL
Status: Recruiting
Last Changed: Apr 04, 2019
First Received: Aug 23, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Bendamustine hydrochloride, Gemcitabine 500 mg, Gemcitabine 700 mg, Gemcitabine 1000 mg, Nivolumab, Rituximab
Locations: First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Oct 03, 2019
First Received: Sep 03, 2018
Disease(s): Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
Intervention(s): Molecular Nanotechnology
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Feb 20, 2019
First Received: Mar 07, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Blinatumomab, Autologous stem cell transplant, Carmustine, Etoposide, Cytarabine, Melphalan, Peripheral blood draws
Locations: Washington University School of Medicine, Saint Louis, Missouri, United States
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
Status: Recruiting
Last Changed: May 10, 2019
First Received: Oct 10, 2017
Disease(s): Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): Ipilimumab, Nivolumab
Locations: Icahn School of Medicine at Mount Sinai, New York, New York, United States
Treatment for Advanced B-Cell Lymphoma
Status: Recruiting
Last Changed: Mar 13, 2019
First Received: May 22, 2013
Disease(s): Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma
Intervention(s): Rituximab, IT Cytarabine
Locations: Roswell Park Cancer Institute, Buffalo, New York, United States
New York Medical College, Valhalla, New York, United States
Levine Children's Hospital, Charlotte, North Carolina, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
University of Utah, Salt Lake City, Utah, United States
... and 1 other locations.